CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition

Aberrant activation of CDK4/6 kinase is the most common somatic event in non-small cell lung cancer (NSCLC). Palbociclib is a highly specific CDK4/6 inhibitor shown to inhibit cell cycle progression and promote cellular senescence. We conducted a phase 2 clinical trial of palbociclib in 19 previousl...

Descripción completa

Detalles Bibliográficos
Autores principales: Gopalan, Priya K., Villegas, Andres Gordillo, Cao, Chunxia, Pinder-Schenck, Mary, Chiappori, Alberto, Hou, Wei, Zajac-Kaye, Maria, Ivey, Alison M., Kaye, Frederic J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324768/
https://www.ncbi.nlm.nih.gov/pubmed/30647837
http://dx.doi.org/10.18632/oncotarget.26424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324768/
https://www.ncbi.nlm.nih.gov/pubmed/30647837
http://dx.doi.org/10.18632/oncotarget.26424

Ejemplares similares